Sanofi: progress in Dupixent for children and teenagers
(CercleFinance.com) - Sanofi announces that the European Commission has extended the marketing authorisation of Dupixent (dupilumab) in the European Union to patients aged 12 to 17 years presenting a moderate-to-severe form of atopic dermatitis and who are candidates for systémic therapy.
Dupixent is now the first biological medicine approved within the EU to treat these patients. Atopic dermatitis, the most common form of eczema, is a chronic inflammatory disease.
Approval followed on from phase III trials showing that it significantly mitigated the intensity of itching, extent and severity of the disease, while improving the skin's healing and quality of life relating to sleep and health.
Sanofi also reports that a pivotal phase III trial evaluating Dupixent (dupilumab) in the treatment of severe atopic dermatitis in children aged six to 11 years has met its primary and secondary endpoints: it is due to be submitted to the FDA in Q4 2019.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Dupixent is now the first biological medicine approved within the EU to treat these patients. Atopic dermatitis, the most common form of eczema, is a chronic inflammatory disease.
Approval followed on from phase III trials showing that it significantly mitigated the intensity of itching, extent and severity of the disease, while improving the skin's healing and quality of life relating to sleep and health.
Sanofi also reports that a pivotal phase III trial evaluating Dupixent (dupilumab) in the treatment of severe atopic dermatitis in children aged six to 11 years has met its primary and secondary endpoints: it is due to be submitted to the FDA in Q4 2019.
Copyright (c) 2019 CercleFinance.com. All rights reserved.